Efrain is a molecular virologist with over 20 years’ experience in viral vector technologies. In the late 1990s, Efrain worked at Baylor College of Medicine(USA) on developing and understanding the first-generation adenoviral vectors for gene therapy applications. After completing his PhD in molecular virology of rotaviruses at the University of Warwick (UK), Efrain carried out post-doctoral work at the UK’s National Virology Centre at The Pirbright Institute, investigating the safety and efficacy of viral vectors for vaccine applications. In 2018 he joined Oxford Biomedica tasked with leading the company’s work in developing new viral vectored-based gene therapy products and technologies. Efrain also holds an MBA from The Open University and a Senior Leadership Master’s Degree in Advanced Therapeutics from the UK’s Institute for Apprenticeships and Technical Education. Efrain joined NewBiologix in 2024 with the aim of helping the team develop innovative solutions for addressing current manufacturing challenges in the field of vector production for gene therapy.